SOURCE: Wall Street Equity Research

Wall Street Equity Research

September 24, 2010 08:44 ET

Research on Akorn and Celldex Therapeutics -- Substance Diagnostics Hope September Growth Continues

JOHANNESBURG, SOUTH AFRICA--(Marketwire - September 24, 2010) - offers world class analysis on diagnostic substances companies Akorn Inc. (NASDAQ: AKRX) and Celldex Therapeutics Inc. (NASDAQ: CLDX). Sign up today at to receive free research reports on these companies.

The diagnostic substances industry climbed this week on the coat tails of a strong September for the healthcare sector. is a specialized website where investors can have full access to free reports on diagnostic substances stocks; traders looking for analyst opinions on Akorn Inc. and Celldex Therapeutics Inc. are welcomed to sign up for a free one year membership at

Despite the strong September, volatility remains for the industry though. The diagnostic substances industry is highly dependent upon much larger pharmaceutical companies and the partnerships formed between them. The still rebounding economy has led many major pharmaceutical companies to reevaluate their relationships with diagnostic substances companies. Visit us at to understand the catalysts and forces driving or affecting diagnostic substances companies in today's economic environment.

The latest rounds of re-evaluations have led to many severed partnerships recently. Essentially, in a healthy economy big pharmaceutical companies are willing to accept larger risk reward ratios with their partnerships with diagnostic substance companies. The weakened economy has lowered the tolerable risk reward ratio and led to the termination of several partnerships. During the first of September, Pfizer decided to withdraw from a deal with Celldex Therapeutics Inc. The deal was to develop a brain tumor vaccine. The has also compiled a free research on Celldex Therapeutics Inc. that can be downloaded now by signing up at

Overall, the strong September for healthcare bodes well for diagnostic substance companies but it will likely take several more months of consistent performance to raise risk reward ratios back to a favorable level. 

On a positive note for the industry, Akorn Inc. has seen a surge in institutional investors in the past few months. Shareholders and investors can access the free research Akorn Inc. now by signing up at

About Wall Street Equity Research: 
Wall Street Equity Research looks to bring simplicity and highly sophisticated research to an ever-changing investing environment. Wall Street Equity Research has been partnering with a number of North American and Emerging Economies analysts to bring you the best of both continents in terms of market analysis and analytical opinions. 

Contact Information